Evolent Health, Inc. (NYSE:EVH) Shares Acquired by Sterling Capital Management LLC

Sterling Capital Management LLC increased its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 36.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 106,344 shares of the technology company’s stock after purchasing an additional 28,424 shares during the quarter. Sterling Capital Management LLC owned 0.09% of Evolent Health worth $1,196,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Pilgrim Partners Asia Pte Ltd acquired a new stake in Evolent Health in the fourth quarter valued at approximately $26,000. R Squared Ltd purchased a new stake in Evolent Health during the 4th quarter worth $31,000. AlphaQuest LLC lifted its holdings in Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock worth $34,000 after buying an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after buying an additional 2,358 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Evolent Health during the fourth quarter valued at about $61,000.

Insider Buying and Selling at Evolent Health

In related news, Director Diane Holder bought 2,735 shares of the stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.33 per share, with a total value of $25,517.55. Following the purchase, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brendan B. Springstubb purchased 5,000 shares of Evolent Health stock in a transaction dated Tuesday, March 4th. The stock was bought at an average cost of $8.75 per share, with a total value of $43,750.00. Following the completion of the purchase, the director now owns 11,842 shares in the company, valued at approximately $103,617.50. This trade represents a 73.08 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 74,000 shares of company stock worth $666,315. 1.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EVH has been the topic of several recent analyst reports. Oppenheimer cut their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. JPMorgan Chase & Co. decreased their price target on shares of Evolent Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday, March 10th. Canaccord Genuity Group cut their price target on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Royal Bank of Canada decreased their price objective on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, January 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 target price on shares of Evolent Health in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.64.

Evolent Health Stock Down 4.9 %

Shares of Evolent Health stock opened at $9.32 on Wednesday. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -11.36 and a beta of 1.20. Evolent Health, Inc. has a twelve month low of $8.35 and a twelve month high of $33.63. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The business’s 50 day simple moving average is $9.69 and its 200-day simple moving average is $13.58.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The company had revenue of $646.54 million during the quarter, compared to analyst estimates of $650.92 million. Equities research analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.